HLVX vs. PRME, PROK, ALLO, NVAX, VALN, CGEM, MESO, FATE, EXAI, and ALEC
Should you be buying HilleVax stock or one of its competitors? The main competitors of HilleVax include Prime Medicine (PRME), ProKidney (PROK), Allogene Therapeutics (ALLO), Novavax (NVAX), Valneva (VALN), Cullinan Oncology (CGEM), Mesoblast (MESO), Fate Therapeutics (FATE), Exscientia (EXAI), and Alector (ALEC). These companies are all part of the "biological products, except diagnostic" industry.
Prime Medicine (NYSE:PRME) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends, community ranking and profitability.
HilleVax is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.
70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 86.4% of HilleVax shares are held by institutional investors. 24.3% of Prime Medicine shares are held by company insiders. Comparatively, 29.3% of HilleVax shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Prime Medicine has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, HilleVax has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.
Prime Medicine's return on equity of -48.17% beat HilleVax's return on equity.
In the previous week, Prime Medicine had 11 more articles in the media than HilleVax. MarketBeat recorded 13 mentions for Prime Medicine and 2 mentions for HilleVax. HilleVax's average media sentiment score of 0.32 beat Prime Medicine's score of -0.20 indicating that Prime Medicine is being referred to more favorably in the media.
Prime Medicine received 1 more outperform votes than HilleVax when rated by MarketBeat users. However, 100.00% of users gave HilleVax an outperform vote while only 69.23% of users gave Prime Medicine an outperform vote.
Prime Medicine currently has a consensus target price of $16.89, indicating a potential upside of 277.83%. HilleVax has a consensus target price of $30.67, indicating a potential upside of 144.55%. Given HilleVax's higher possible upside, analysts clearly believe Prime Medicine is more favorable than HilleVax.
Summary
Prime Medicine beats HilleVax on 8 of the 15 factors compared between the two stocks.
Get HilleVax News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HLVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HilleVax Competitors List
Related Companies and Tools
